FDA WEIGHS THREE SWITCHES FOLLOWING PANEL REJECTIONS

WASHINGTON (FNS) -- Applications to market over-the-counter versions of Rogaine (monoxidil), Tagamet (cimetidine) and Pepcid (famotidine) are pending final review by the Food and Drug Administration.Approval of any of the three applications is considered unlikely, because FDA advisory panels last month recommended against switching the drugs to OTC status. FDA typically, although not always, follows

WASHINGTON (FNS) -- Applications to market over-the-counter versions of Rogaine (monoxidil), Tagamet (cimetidine) and Pepcid (famotidine) are pending final review by the Food and Drug Administration.

Register to view the full article